GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verona Pharma PLC (GREY:VNAPF) » Definitions » Cyclically Adjusted PB Ratio

Verona Pharma (Verona Pharma) Cyclically Adjusted PB Ratio : (As of May. 24, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Verona Pharma Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Verona Pharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Verona Pharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verona Pharma Cyclically Adjusted PB Ratio Chart

Verona Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.91 1.65 5.57 3.81

Verona Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.15 4.22 3.18 3.81 3.02

Competitive Comparison of Verona Pharma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Verona Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verona Pharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verona Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Verona Pharma's Cyclically Adjusted PB Ratio falls into.



Verona Pharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Verona Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Verona Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.468/131.6000*131.6000
=0.468

Current CPI (Mar. 2024) = 131.6000.

Verona Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201206 1.031 95.600 1.419
201212 0.685 97.300 0.926
201306 0.536 98.000 0.720
201312 0.458 99.200 0.608
201406 1.169 99.800 1.541
201412 0.971 99.900 1.279
201506 0.714 100.100 0.939
201512 0.399 100.400 0.523
201606 0.108 101.000 0.141
201609 0.000 101.500 0.000
201612 0.828 102.200 1.066
201703 0.000 102.700 0.000
201706 1.156 103.500 1.470
201709 1.087 104.300 1.372
201712 1.028 105.000 1.288
201803 0.876 105.100 1.097
201806 0.832 105.900 1.034
201809 0.807 106.600 0.996
201812 0.764 107.100 0.939
201903 0.720 107.000 0.886
201906 0.599 107.900 0.731
201909 0.470 108.400 0.571
201912 0.406 108.500 0.492
202003 0.303 108.600 0.367
202006 0.222 108.800 0.269
202009 0.428 109.200 0.516
202012 0.399 109.400 0.480
202103 0.372 109.700 0.446
202106 0.327 111.400 0.386
202109 0.350 112.400 0.410
202112 0.308 114.700 0.353
202203 0.263 116.500 0.297
202206 0.231 120.500 0.252
202209 0.494 122.300 0.532
202212 0.480 125.300 0.504
202303 0.576 126.800 0.598
202306 0.569 129.400 0.579
202309 0.549 130.100 0.555
202312 0.519 130.500 0.523
202403 0.468 131.600 0.468

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Verona Pharma  (GREY:VNAPF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Verona Pharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Verona Pharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Verona Pharma (Verona Pharma) Business Description

Traded in Other Exchanges
Address
3 More London Riverside, London, GBR, SE1 2RE
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. The company is engaged in pharmaceutical development.